Hims & Hers Health: Analysts remain bearish By Investing.com Hims & Hers Health: Analysts remain bearish…
Hims & Hers: Scharfe Korrektur nach Ende der FDA-Ausnahmeregelung und Cigna-Offensive Regulatorische Änderungen und neue Preisstrategien bremsen den Höhenflug der Telemedizin-Aktie Konkurrenz durch Versicherer wächst Nach einem starken…
Citi says Evernorth plan ‘slight headwind’ to Hims & Hers Citi keeps a Sell rating on Hims Hers (HIMS) with a $30 price target after Cigna’s (CI) Evernorth announced…
Hims & Hers Health: Analysts remain bearish By Investing.com Hims & Hers Health: Analysts remain bearish…
Hims & Hers falls after Cigna offers cheaper obesity drug plan Shares of Hims Hers (HIMS) are down $4.49, or 8%, to $53.51 near the open after Cigna (CI) said…
Hims & Hers growth moderated in April, says BofA BofA analyst Allen Lutz says Hims Hers’ observed sales data continues to weaken sequentially, reporting that year-over-year observed sales…
Up 157% in 2025, Is It Too Late to Buy Hims & Hers Stock? Hims & Hers (NYSE: HIMS) has put investors on a roller coaster ride in 2025.…